Empire Blue Cross/Blue Shield Reverses Course
Empire Blue Cross/Blue Shield has agreed to reverse a decision made last month to no longer cover services oncological patients receive from facilities run by Integrated Medical Professionals of Farmingdale. Its 52 locations serviced 1300 Long Islanders, including East Enders who already had to drive up the island to find [...]
In NYC Subway, CyberKnife Prostate Cancer Ads Mislead
Survey Respondents Influenced by Claims Direct-to-consumer (DTC) advertising about the radiotherapy (RT) known as CyberKnife (CK), which is currently omnipresent in the New York City transit system, creates "inaccurate impressions" about the treatment's "comparative effectiveness and safety" in prostate cancer, according to new research. That conclusion was made by investigators [...]
Empire Blue Cross/Blue Shield reverses decision to drop LI providers
Last month, the insurer said it was removing Integrated Medical Professionals of Farmingdale, a urology and radiation oncology practice, and Port Jefferson Station-based New York Cancer & Blood Specialists, from its Medicare Advantage HMO and Dual Special Needs Plan networks.
CMS gives radiation therapy providers a break — but bigger changes may be coming
CMS is letting radiation oncologists bill some E/Ms with superficial radiation therapy (SRT) that had previously been bundled. But those providers should look out: this may be a preliminary step before CMS puts in new regulations that may shake up their reimbursement. […]
Empire Blue Cross/ Blue Shield drops another provider from some plans
Empire Blue Cross/Blue Shield said about 7,000 patients of a Farmingdale-based urology and radiation oncology practice have been notified their doctors are being taken out of the network. Dr. Deepak Kapoor says “We have decades of doctor-patient relationships impacted,” and continued “Our hope is we can talk to the insurer [...]
Letter: IMRT ownership study methodology unsound
In a letter to the editor in Urology Times, Deepak A. Kapoor, MD addressed the conclusions of Borza et al on the issue of financial incentives in fee-for-service medicine impacting clinical decision-making (“IMRT ownership appears to influence PCa treatment,” October 2018, p6). To find out why Dr. Kapoor declares the [...]
